Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Personalis, Inc. on May 17, 2023. The meeting was conducted virtually, with a record date of March 20, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 87.13% of outstanding shares (40,755,740 shares) attended the meeting, constituting a quorum. Three proposals were voted upon:
- Proposal 1 (Election of Directors): Stockholders elected Olivia K. Bloom and Woodrow A. Myers, Jr., M.D. as Class I directors.
- Olivia K. Bloom: 29,040,904 votes for; 247,304 votes withheld.
- Woodrow A. Myers, Jr., M.D.: 25,438,086 votes for; 3,850,122 votes withheld.
- Broker non-votes: 11,467,532 for both nominees.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes For: 40,554,309
- Votes Against: 38,903
- Abstentions: 162,528
- Proposal 3 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Votes For: 28,615,039
- Votes Against: 475,452
- Abstentions: 197,717
- Broker Non-Votes: 11,467,532
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Verify the total number of shares outstanding as of the record date (46,774,490) to confirm the 87.13% participation rate.
- Note the significant number of broker non-votes (11,467,532) on the director election and executive compensation proposals, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the term of the newly elected directors, which extends until the 2026 annual meeting.
- Review the definitive proxy statement (Schedule 14A filed April 5, 2023) for detailed background on the director nominees and executive compensation rationale.